EMA Panel Backs Foundayo (Orforglipron) for EU Authorisation
TL;DR: EMA’s CHMP backed Lilly’s oral GLP-1 Foundayo (orforglipron) on 15 Oct 2026; the European Commission decision is still pending.
What Did the EMA Committee Recommend on 15 October 2026?
On 15 October 2026 the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on Foundayo (orforglipron), an oral GLP-1 receptor agonist developed by Eli Lilly, and the agency published it on 16 October.[1][2] According to the reports, the recommended uses are adult weight management and, separately, type 2 diabetes in adults. The applicant is listed as Eli Lilly Nederland B.V.[2]
The weight-management dossier is reported to rest on two studies enrolling more than 4,740 adults, with placebo-controlled treatment lasting 72 weeks. The most commonly reported adverse reactions were nausea, vomiting and diarrhoea.[2] We deliberately do not reproduce outcome percentages here: this page tracks the regulatory step, not trial performance.
Scope of this summary. We report a regulator’s public opinion on a licensed-pathway medicine. Nothing here is guidance for any individual, and it concerns no product supplied by Velox Peptides.
Is a CHMP Opinion the Same as EU Approval?
No. A CHMP opinion is a scientific recommendation. The European Commission issues the legally binding marketing authorisation, typically some weeks later, and pricing and reimbursement are then decided by each Member State.[2] Some aggregator pages circulating this week blur that distinction and conflate Foundayo with Novo Nordisk’s oral Wegovy, which the Commission approved in July 2026; our summary of the oral Wegovy EU approval covers that separate decision.[3]
One analyst quoted in the coverage expects an EU launch for obesity around the end of 2026, with the diabetes indication depending on national reimbursement.[4] That is an analyst expectation, not a regulatory date.
How Does This Connect to the UK Position?
The EU decision does not apply in Great Britain, where the Medicines and Healthcare products Regulatory Agency (MHRA) runs its own process. Our tracker of Foundayo and the MHRA sets out the UK status separately. For researchers following regulatory divergence, Northern Ireland adds a further wrinkle, because EU medicines rules continue to apply there under the Windsor Framework.
How Does Orforglipron Differ from Retatrutide?
Orforglipron is a non-peptide, orally available small molecule acting at the GLP-1 receptor. Retatrutide is a different class: an investigational injectable peptide that engages GIP, GLP-1 and glucagon receptors, still in Phase 3 development with a regulatory filing planned for 2027 according to Eli Lilly. Our explainers on whether retatrutide is a GLP-1 and the October 2026 retatrutide evidence status keep the two programmes apart.
For laboratory work the point is categorical. A CHMP opinion attaches to one sponsor’s licensed-pathway product and manufacturing dossier. It says nothing about research-grade reagents, which are not medicines. Velox Peptides supplies retatrutide solely as an HPLC-verified in vitro research reagent; specifications are on the retatrutide compound page.
What Should Researchers Watch Next?
Three items follow from this opinion: the European Commission’s formal decision and its date; the published CHMP assessment documents, which typically describe the evidence base in more detail than press summaries; and whether the MHRA signals any reliance on the EU outcome. We will update this guide when the Commission decides. Because the EMA page itself could not be retrieved during writing, treat the figures above as secondary-source reporting and check the agency’s October 2026 CHMP outputs directly.
Velox Peptides supplies compounds solely as in vitro research reagents for qualified researchers, with batch documentation, and does not represent any product as suitable for human or veterinary use.
References
- Lovguiden (Denmark). EMA anbefaler Foundayo (English edition, summarising the EMA announcement). 16 October 2026. lovguiden.dk
- Pharmaceutical Executive. EMA panel backs Lilly’s Foundayo for obesity and type 2 diabetes in Europe. 16 October 2026. pharmexec.com
- Velox Peptides. Oral Wegovy wins EU-wide approval. July 2026 (internal summary). veloxpeps.com
- Placera (Sweden). EMA ger rekommendation för Eli Lillys Foundayo. 16 October 2026. placera.se
Frequently Asked Questions
What did the EMA’s CHMP decide about Foundayo on 15 October 2026?
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending an EU marketing authorisation for Foundayo (orforglipron), Eli Lilly’s oral GLP-1 receptor agonist, for adults for weight management and for type 2 diabetes. The opinion was published on 16 October 2026. It is a recommendation, not an approval.
Is Foundayo approved in the EU yet?
Not according to the sources reviewed. The European Commission takes the final legal decision after a CHMP opinion, and pricing and reimbursement are then decided country by country. Oral Wegovy (semaglutide) is a separate product that the Commission approved in July 2026.
Is orforglipron the same kind of molecule as retatrutide?
No. Orforglipron is an oral, small-molecule GLP-1 receptor agonist. Retatrutide is an investigational injectable peptide that engages the GIP, GLP-1 and glucagon receptors. Both are Eli Lilly programmes, but they are at different regulatory stages.
Does this opinion apply to research reagents?
No. A CHMP opinion concerns one sponsor’s medicinal product and its dossier. Velox Peptides supplies compounds only as in vitro research reagents, and this page is a news summary, not medical or regulatory advice.
Where can I read the primary source?
The opinion is part of the EMA’s October 2026 CHMP meeting outputs on ema.europa.eu; trade and regional outlets summarised it on 16 October 2026. We link the secondary reports in the references because we could not retrieve the EMA page directly at the time of writing.